Biomica Ltd., a subsidiary of Evogene Ltd. (EVGN), Thursday announced positive data from its ongoing Phase 1 trial of microbiome-based immuno-oncology candidate, BMC128, in combination with nivolumab, for the treatment of patients with non-small cell lung cancer or NSCLC, melanoma, or renal cell carcinoma or RCC.
The biotechnology company stated that 55 percent of candidates showed sustained clinical benefit, with notable durations of response of over 16 weeks and with one patient exceeding 80 weeks.
Further, 100 percent of RCC patients and 60 percent of NSCLC patients in the study demonstrated positive clinical outcomes, indicating potential efficacy across different cancer types.
Currently, Evogene's stock is trading at $0.8, up 8.15 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.